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A B S T R A C T
Objective: To assess the extent to which patients feel they have received enough information on
cardiovascular drugs and experienced counseling at the pharmacy. In addition, to identify factors that
are predictors for patient satisfaction with the information received.
Methods: Fifteen community pharmacies participated. New and chronic users of cardiovascular
medication received a questionnaire containing sociodemographic and health questions, a measure of
satisfaction with information received (SIMS), beliefs about medication (BMQ), and frequency of
pharmacy counseling.
Results: Of the 578 respondents, 335 (58%) indicated to be unsatisﬁed with the information received on 3
or more SIMS items. Patients’ age, beliefs about medication, duration of cardiovascular treatment and
use of antithrombotics predicted patients’ satisfaction with information received. Two-thirds of patients
reported ‘never’ to have experienced 5 of 8 counseling activities at the pharmacy.
Conclusions: A considerable proportion of patients are unsatisﬁed with the information received on
cardiovascular medication. The majority of patients have only received a limited scope of medication
counseling at the pharmacy.
Practice implications: Information and counseling should be tailored to patients’ needs and concerns
about cardiovascular medication and the experience patients already have with treatment. Pharmacists
could enhance their role in supporting patients using cardiovascular medication.
 2011 Elsevier Ireland Ltd. 
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Guidelines for cardiovascular risk management recommend
pharmacological treatment for patients who are at increased risk of
fatal cardiovascular disease [1]. Thus patients with multiple risk
factors face a lifetime of taking several concurrent medications to
reduce their risk of a cardiovascular event.
In practice, patients appear to have difﬁculty adhering to drug
treatment [2,3]. Patients are often reluctant to take medication
because of doubts regarding the need for drug therapy or concerns
about possible adverse effects of their cardiovascular medications.
[4–7]. Also, complex drug regimens may cause confusion, and
multiple dosing can be difﬁcult to organize [2,3,6].
Health care providers need to address patients’ concerns and
problems and motivate patients to continue treatment. Studies* Corresponding author at: UPPER, Division Pharmacoepidemiology and Clinical
Pharmacology, Utrecht University, P.O. Box 80082, 3508 TB Utrecht, The
Netherlands. Tel.: +31 30 253 7309; fax: +31 30 253 9166.
E-mail address: e.c.g.vangeffen@uu.nl (Erica C.G. van Geffen).
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doi:10.1016/j.pec.2011.04.004
Open access under the Elsevier OA license.suggest that interventions such as giving verbal and written
information can improve adherence to cardiovascular drugs [8,9].
However, patients’ information needs might not always be met, due
to differing perspectives between health care provider and patient as
to the type of information that is needed [2]. It has been shown that
information given during general practitioner (GP) consultation is
brief, and patients may require further information, misunderstand
information, or fail to recall important details [2,10]. Furthermore,
patients’ needs and quest for information will continue and change
over time in response to their personal experiences with the
medication [2,6,11]. Therefore it is possible that the needs of new
medication users differ from those of chronic users, i.e. patients who
have been taking this medication for a period of time.
Community pharmacists may play an important role in the
patient-centered management of medication issues by informing
and counseling patients [12]. They generally see patients more
frequently and are more accessible than other health care providers,
and are the last to see the patient before drug treatment is initiated.
Thus, they have the opportunity to reiterate important points and
address problems and questions, at the moment of dispensing [6,12].
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and counseling on cardiovascular medication in The Netherlands is
unknown. Therefore, we examined the extent to which patients
feel they have received enough information on cardiovascular
medication as well as the extent to which patients experienced
counseling at the pharmacy. In addition, we aimed to identify
predictors for patient satisfaction with information received.
2. Methods
In this study we conducted a cross sectional postal survey of
patients taking cardiovascular medicines identiﬁed from commu-
nity pharmacy dispensing records.
2.1. Setting
Community pharmacists belonging to the Utrecht pharmacy
practice network for education and research (UPPER) of the
department of Pharmaceutical Sciences of Utrecht University were
invited to participate in this study. This network consists of
approximately 900 community pharmacies who regularly partici-
pate in research and traineeships for pharmacy students of this
department. Of the pharmacies, 58 responded positively within two
weeks. Of these, 15 pharmacies were selected. In this selection, we
tried to achieve diversity in terms of the degree of urbanisation,
percentage of second generation immigrants and percentage of
patients aged over 65 years. Data were obtained from Statistics
Netherlands (www.cbs.nl). Of the participating pharmacies, three
were located in an ‘extremely urbanised’ setting (second generation
immigrants ranging from 24.3 to 62.0%, age over 65 ranging from 5.7
to 8.5%), four in a ‘strongly urbanised’ setting (second generation
immigrants ranging from 6.3 to 16.9%, age over 65 ranging from 7.2
to 20.1%), two in a ‘moderately urbanised’ setting (second generation
immigrants 5.4% and 7.3%, age over 65 5.9 and 9.2%), four in a ‘hardly
urbanised’ setting (second generation immigrants ranging from 1.1
to 3.9%, age over 65 ranging from 14.8 to 16.8%), and two were
located in a ‘non urbanised’ setting (second generation immigrants
1.1 and 1.3%, age over 65 9.4 and 14.7%).
2.2. Population
Antihypertensive drugs and statins are the key therapies for
modifying overall cardiovasular risk and are advised for patients
with a 10-year mortality risk for cardiovascular disease of over 10%
[1]. In April 2010, the participating pharmacists selected patients
aged over 18, who had presented a prescription for cardiovascular
medication, either an antihypertensive drug (ATC C02, C03, C07, C08,
C09) or a statin (C10), within the previous 3 months. The pharmacies
use automated dispensing records that provide detailed drug
utilization information. Since the majority of Dutch patients are
registered with a single community pharmacy, pharmacy records
are virtually complete with regard to prescription drugs [13].The
pharmacists sent the anonymous dispensing records to the
investigators who identiﬁed new and chronic users of cardiovascular
medication. New users of cardiovascular drugs were deﬁned as
patients who had not used any cardiovascular medicines (either ATC
C02, C03, C07, C08, C09 or C10) in the two years before the ﬁrst
prescription of the cardiovascular medicine in the selection period.
Chronic users were deﬁned as patients who had ﬁlled more than 40
prescriptions of cardiovascular medicines in the previous three
years, which was considered to be a substantial amount of visits of
the patient to the pharmacy; in The Netherlands it is usual practice to
dispense a 14 day supply for new prescriptions, and subsequent
prescriptions are usually for a 90 day supply. We aimed to invite
1500 patients, divided into two groups of approximately equal size.
Because of an anticipated lower response rate in the group of newusers compared to the chronic users, we decided to invite all new
users and to invite a random sample of the chronic users. Fig. 1 shows
the selection of the study participants. The selected patients were
sent a mailed questionnaire and after three weeks a reminder card
was sent. The study was approved by the Institutional Review Board
of the Pharmacoepidemiology and Clinical Pharmacology division of
Utrecht University.
2.3. Measures
Patients received a questionnaire that contained sociodemo-
graphic and health questions, a measure of satisfaction with
information received about medication, a measure of beliefs on
medication, and questions on the frequency of counseling at the
pharmacy. Information on medication use was extracted from the
pharmacy dispensing records.
2.3.1. Satisfaction with information about cardiovascular medication
The extent to which patients feel they have received enough
information about cardiovascular medication was assessed using
the Satisfaction with Information about Medicines Scale (SIMS)
[14]. The SIMS consists of 17 items, each referring to a particular
aspect of medicine use. Of these, two items (‘what your medicine is
called’ and ‘whether the medication will affect your sex life’) were
excluded because of expected difﬁculty for patients taking
multiple cardiovascular medicines to rate these items. For each
of the 15 items, patients were asked to rate the amount of
information they have received about their cardiovascular
medication as a whole. Those reporting that the information
was ‘‘about right’’ or indicating ‘‘none needed’’ were classiﬁed as
satisﬁed (scored 1). Those reporting that the information was ‘‘too
much’’, ‘‘too little’’ or indicating ‘‘none received’’ were classiﬁed as
dissatisﬁed (scored 0). The responses can be analyzed at different
levels [14]. The ratings for each individual item were examined to
identify speciﬁc types of information that patients feel they are
lacking. In addition, a total satisfaction rating was obtained by
summing the scores for all 15 items. The total scale scores showed
good internal reliability: the Cronbach’s alpha coefﬁcient was 0.94.
Scores range from 0 to 15 with high scores indicating a high degree
of overall satisfaction with the amount of medication information
received. We chose a total score of 12 or less to deﬁne the patients
being unsatisﬁed with the information on cardiovascular medica-
tion received because the median score of all patients was 12, and
we considered three or more items where information was lacking
a reasonable deﬁnition of overall dissatisfaction.
2.3.2. Sociodemographic, health and medication characteristics
Sociodemographic characteristics included age, gender, ethnic
origin and level of education. Age and gender were retrieved from
the automated dispensing records. Educational level was divided
into three categories: none/primary school, secondary school and
higher professional education/university. Health characteristics
included Body mass index and smoking behavior. Body mass index
was calculated by the investigators from weight and height as
provided by the patient. Patients were also asked to indicate
whether they suffered from either hypertension, high cholesterol,
obesity or diabetes. Medication characteristics were extracted from
the pharmacy dispensing record, and included any use (2 or more
prescriptions) of antithrombotics, antihypertensives, statins, anti-
diabetics, benzodiazepines and antidepressants in the six months
before the selection date. Patients on antithrombotic treatment
were considered to have an increased risk for a cardiovascular event
either because of a previous cardiovascular event, angina pectoris or
cardiac arrhythmias. Depression and anxiety frequently coexist with
cardiovascular disease and therefore antidepressant and benzodi-
azepine use was taken into account.
Rando m sample of 657  chron ic 
users of  cardiovasc ular 
med ication  were sen t a 
questionna ire
889 starters (1 or 2 presc ription s of 
cardiovasc ular med ication  in the 
previou s 3 mon ths, and  no  
cardiovasc ular drug  in the  previou s 2 
yea rs) were sen t a que stionna ire
4504 chron ic users (at lea st 
40 presc ription s of 
cardiovasc ular med ication  in 
previou s 2 yea rs)
527 no n-
respond ents
362 respond ents
(40 .7%)
371 no n-
respond ents
286 respond ents
(43 .5%)
332 starters in ana lys is 
(key items complete)
246 chron ic users in 
analys is (key items 
complete)
Patien ts who :
were aged  over 18
had dispen sed  at  lea st  1 presc ription  for cardiovasc ular 
med ication  (an tihype rten sive or statin) within previou s 3 mon ths
Fig. 1. Flowchart showing selection and response of the study participants: new users and chronic users of cardiovascular medication.
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Patients’ beliefs about cardiovascular medicines were assessed
using the validated beliefs about medicines questionnaire (BMQ-
speciﬁc) [15]. The BMQ-speciﬁc comprises two scales: the necessity
scale assessing beliefs about the necessity of prescribed medications
and the concerns scale assessing concerns about prescribed
medications. Each item of the BMQ is scored using a 5-point Likert
scale (1 = strongly disagree, 2 = disagree, 3 = uncertain, 4 = agree,
5 = strongly agree). Individual item scores were summed to generate
the necessity and concerns scale score, ranging from 5 to 25. Higher
scores on the scales indicate stronger beliefs in the concepts
represented by the scale. The separate necessity and concerns scales
were split at the median to generate four attitudinal groups:
accepting (high necessity, low concerns), ambivalent (high necessi-
ty, high concerns), skeptical (low necessity, high concerns),
indifferent (low necessity, low concerns) [16].
2.3.4. Frequency of counseling on cardiovascular medication at the
pharmacy
The subscale on counseling of the validated consumer quality
index pharmaceutical care was used to measure patients’
experiences with counseling at the pharmacy about their
cardiovascular medication [17]. The subscale consists of eight
items, each referring to a speciﬁc counseling activity. For each item,patients were asked to indicate how often they experienced the
activity with regard to their cardiovascular medication, on a 4-
point Likert scale (‘‘never’’, ‘‘sometimes’’, ‘‘often’’, ‘‘always’’). A total
pharmacy counseling score was obtained by summing the scores
for each item. Patients reporting that they ‘‘never’’ experienced the
particular counseling activity were scored ‘‘0’’, those reporting
‘‘sometimes’’, ‘‘often’’ or ‘‘always’’ were scored ‘‘1’’. Total scores
range from 0 to 8. The total pharmacy counseling score showed
good internal reliability with a Cronbach’s alpha coefﬁcient of 0.84.
2.3.5. Primary source of information
Patients were asked two further questions: ‘‘Which health care
professional was the most important source of information on your
cardiovascular medication?’’ and ‘‘Which health care professional
would you contact ﬁrst if you have questions or problems with
your cardiovascular medication?’’. Patients could choose between
the answer categories ‘GP’, ‘GP nurse practitioner’, ‘pharmacist or
pharmacy assistant’, ‘cardiologist’, ‘specialist’, ‘hospital nurse’ or
‘other’.
2.4. Data analysis
Sociodemographic characteristics, medication use and beliefs
groups were compared among patients who were unsatisﬁed with
Table 1
Sociodemographic, health and medication characteristics of responding patients.
% (n) n = 578
Sociodemographica
Female gender 47.6 (275)
Age
18–50 15.1 (87)
51–60 27.9 (161)
61–70 32.4 (187)
>71 24.7 (143)
Educational levelc
None/primary school 38.5 (218)
Secondary school 41.0 (232)
College/university 20.5 (116)
Non-western background 4.9 (28)
Healtha
Cardiovascular diseasesd
Hypertension 67.3 (379)
High blood cholesterol 43.5 (245)
Diabetes 23.6 (133)
Obesity 9.9 (56)
None of these 12.4 (70)
Body mass index
Underweight (<18.5) 0.4 (2)
Normal range (18.5–25) 32.4 (183)
Overweight (25–30) 43.6 (246)
Obese (30) 23.6 (133)
Smoking behavior
Current smoker 16.0 (92)
Ex-smoker 50.2 (289)
Never smoked 33.9 (195)
Medication useb
Antihypertensives 84.6 (489)
Statins 50.2 (290)
Antithrombotics 33.9 (196)
Antidiabetics 19.0 (110)
Benzodiazepines 9.3 (54)
Antidepressants 8.8 (51)
a Sociodemographic and health characteristics were obtained through the
questionnaire.
b Medication use variables were extracted from the pharmacy dispensing
records.
c Numbers do not total 578 for each item, because some patients did not
complete all questions.
d Numbers exceed 578 as patients could indicate more than one disease.
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score  12) and patients who indicated that they were satisﬁed
with the information received about cardiovascular medication
(SIMS > 12). To identify patients’ characteristics that predicted
being unsatisﬁed with the information received on cardiovascular
medication, univariate and multivariate logistic regression models
were examined. Characteristics with p-values  0.10 in the
univariate models were considered for inclusion in the full
multivariate logistic regression.
Descriptive analyses were used to describe patients’ percep-
tions of pharmacy counseling. To explore differences in the health
care professional most important to patients the Chi-square test
was used. The total pharmacy counseling scores were compared
between new and chronic users of cardiovascular medication,
antithrombotic and non-antithrombotic users and the four beliefs
groups using the one-way analysis of variance (ANOVA).
Data from the automated dispensing records were used to
explore possible bias in the selection of participants. Respondents
and non-respondents were compared by age, sex and medication
use using the Chi-square test.
Data were analyzed using SPSS for Windows, version 16.0.
3. Results
3.1. Selection and response
Fig. 1 shows the selection and response of the study
participants, i.e. new users and chronic users of cardiovascular
medication. The questionnaire was received from 40.7% (n = 362)
of the new users and 43.5% (n = 286) of the chronic users. Thirty
new users and forty chronic users had to be excluded because they
had not completed the key items, leaving 332 new users and 246
chronic users who were included in the analysis. Table 1 shows the
basic characteristics of these respondents.
Comparing respondents (n = 648) and non-respondents
(n = 898), respondents were older (mean age 64.1 vs. 61.4;
p < 0.001); especially patients aged 18–50 years old were
underrepresented among respondents. Furthermore, respondents
less frequently used benzodiazepines (9.9% vs. 15.8%; p = 0.001)
and antidepressants (8.5% vs. 13.5%; p = 0.002) as concomitant
medication. There were no signiﬁcant differences between
respondents and non-respondents with regard to the use of
cardiovascular medication (antithrombotics, statins, antihyper-
tensives) or antidiabetics.
3.2. Patients’ satisfaction with information on cardiovascular
medication
Of all respondents, 30.8% (n = 178) were completely satisﬁed
with all items of the SIMS. Satisfaction mainly resulted from
patients having received ‘about right’ information; between 3.3%
and 8.6% of all respondents reported that information on the
particular aspect of medicine use was not needed.
In almost all cases, dissatisfaction resulted from patients
reporting having received too little or no information; for each
item less than 1% of all respondents reported to have received too
much information. Patients were particularly dissatisﬁed with
information on how long the medicine would take to act (43.8% of
all respondents indicated to be unsatisﬁed), how you could tell if it
is working (46.4% of all respondents), whether the medicine has
any side effects (44.3% of all respondents), what the risks are of
getting side effects (49.7% of all respondents), what you should do
if you experience unwanted side effects (49.8% of all respondents),
whether the medicine interferes with other medicines (43.3% of all
respondents) and what you should do if you forget to take a dose
(44.5% of all respondents).Table 2 shows the patient characteristics associated with
patients’ satisfaction with the information received on cardiovas-
cular medication. Patients aged 51–60 (OR 1.21, 95%CI 0.67–2.20)
and 61–70 (OR 2.07, 95% CI 1.27–3.36) were more likely to be
unsatisﬁed with the information received on cardiovascular
medication compared to patients aged over 70. Patients with an
ambivalent (OR 1.69, 95% CI 1.02–2.81), skeptical (OR 2.86, 95% CI
1.60–2.78) and indifferent (OR 1.67, 95% CI 1.00–2.78) attitude
towards cardiovascular medication were more likely to be
unsatisﬁed with the information received compared to patients
with an accepting attitude. In addition, new users of cardiovascular
medication (OR 1.53, 95% CI 1.02–2.28) were more likely to be
unsatisﬁed with the information received on cardiovascular
medication than chronic users. Also, antithrombotic users (OR
1.81, 95% CI 1.21–2.71) appeared to be unsatisﬁed with informa-
tion received on cardiovascular medication more often, compared
to patients who did not use antithrombotics.
3.3. Frequency of counseling on cardiovascular medication at the
pharmacy
Table 3 shows patients’ experiences with the frequency of
pharmacy counseling. Two-thirds of patients reported ‘never’ to
have experienced 5 of 8 counseling activities.
There was a signiﬁcant difference between new and chronic
users of cardiovascular medication (mean scores  SD: 3.77  2.17
vs. 4.33  2.25; p = 0.007). In addition, the counseling scores differed
Table 2
Characteristics associated with patients’ satisfaction with information received on cardiovascular medication.
Satisﬁed with information
receiveda (SIMS > 12)
n = 243 (42.0%)
Unsatisﬁed with information
receiveda (SIMS  12)
n = 335 (58.0%)
Crude ORb (95% CI) Adjusted ORb,c
(95% CI)
Sociodemographic
Female gender 50.6% (123) 45.4% (152) 0.81 (0.58–1.13)
Age
<50 16.0% (39) 14.3% (48) 1.40 (0.82–2.38) 1.21 (0.67–2.20)
51–60 25.9% (63) 29.3% (98) 1.76 (1.12–2.78) 1.83 (1.11–3.02)
61–70 26.7% (65) 36.4% (122) 2.13 (1.36–3.32) 2.07 (1.27–3.36)
>71 31.3% (76) 20.0% (67) Ref Ref
Educational level
None/primary school 42.8% (101) 35.5% (117) Ref
Secondary school 39.0% (92) 42.4% (140) 1.31 (0.90–1.91)
College/university 18.2% (43) 22.1% (73) 1.47 (0.92–2.32)
Non-western background 5.0% (12) 4.8% (16) 0.96 (0.45–2.07)
Health
Body mass index
Underweight (<18.5) 3.4% (8) 1.8% (6) 0.50 (0.16–1.49)
Normal range (18.5–25) 28.7% (68) 31.5% (103) Ref
Overweight (25–30) 42.6% (101) 44.3% (145) 0.95 (0.64–1.41)
Obese (30) 25.3% (60) 22.3% (73) 0.80 (0.51–1.27)
Smoking behavior
Current smoker 14.4% (35) 17.1% (57) 1.37 (0.82–2.27)
Ex-smoker 49.0% (119) 51.1% (170) 1.20 (0.83–1.73)
Never smoked 36.6% (89) 31.8% (106) Ref
Medication beliefs
BMQ-belief groupsd
Accepting 26.7% (62) 16.2% (52) Ref Ref
Ambivalent 28.9% (67) 27.1% (87) 1.55 (0.95–2.52) 1.69 (1.02–2.81)
Sceptical 13.8% (32) 25.9% (83) 3.09 (1.78–5.36) 2.86 (1.60–5.08)
Indifferent 30.6% (71) 30.8% (99) 1.66 (1.03–2.68) 1.67 (1.00–2.78)
Medication use
New users of cardiovascular
medication (vs. chronic users)
51.4% (125) 61.8% (207) 1.53 (1.09–2.13) 1.53 (1.02–2.28)
Antithrombotic users 29.6% (72) 37.0% (124) 1.40 (0.98–1.99) 1.81 (1.21–2.71)
Antihypertensive users 86.8% (211) 83.0% (278) 0.74 (0.46–1.18)
Statin users 52.7% (128) 48.4% (162) 0.84 (0.60–1.17)
Antidiabetic users 21.4% (52) 17.3% (58) 0.77 (0.51–1.17)
Benzodiazepine users 10.3% (25) 8.7% (29) 0.83 (0.47–1.45)
Antidepressant users 11.9% (29) 6.6% (22) 0.52 (0.29–0.93) 0.53 (0.29–0.97)
a SIMS score >12: patients satisﬁed with information received. SIMS score 12: patients unsatisﬁed with information received.
b OR >1: patient group more likely to be unsatisﬁed with the information received compared to reference group. OR <1: patient group more likely to be satisﬁed with the
information received compared to reference group.
c Model included covariates signiﬁcant in the univariate analysis at a p-value less than 0.1, including gender.
d BMQ-belief groups: accepting (high necessity: >16, low concerns: 13), ambivalent (high necessity: >16, high concerns: >13), sceptical (low necessity: 16, high
concerns: >13), indifferent (low necessity: 16, low concerns: 13).
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ambivalent, indifferent and skeptical patients were 4.44  2.08,
4.39  2.2, 3.77  2.17 and 3.48  2.35, respectively (p = 0.002).
There was no signiﬁcant difference between patients using antith-
rombotic medication and patients not using antithrombotics.Table 3
Frequency of counseling on cardiovascular medication at the pharmacy (n = 578).a
Never % (n) 
Did pharmacy staff ask for your experiences with your
cardiovascular medication? (n = 552)
69.2 (382
Did pharmacy staff ask whether you experienced side
effects of your cardiovascular medication? (n = 550)
77.6 (427
Did pharmacy staff think along with you to ﬁnd a
solution when experiencing side effects? (n = 499)
64.9 (324
Was pharmacy staff well acquainted with the medicines
you were using? (n = 529)
7.8 (41)
Did pharmacy staff ask whether you used over-the-counter
medicines along with your prescription medication? (n = 543)
75.1 (408
Did you receive adequate individual counseling at the
pharmacy? (n = 538)
25.5 (137
Did you have the opportunity to ask all your questions
at the pharmacy? (n = 540)
12.8 (69)
Did pharmacy staff ask whether you managed to take
your medicines according to prescription? (n = 547)
68.6 (375
a Numbers do not total 578 for each item, because some patients did not complete 3.4. Primary source of information
Of all patients, 44.5% (257) reported that the GP was the most
important source of information about cardiovascular medication,
followed by the pharmacist or pharmacy assistant (24.7%, n = 143),Sometimes % (n) Often % (n) Always % (n)
) 19.9 (110) 5.8 (32) 5.1 (28)
) 15.1 (83) 4.4 (24) 2.9 (16)
) 15.4 (77) 8.4 (42) 11.2 (56)
 11.0 (58) 18.5 (98) 62.8 (332)
) 12.5 (68) 5.5 (30) 6.8 (37)
) 28.4 (153) 21.6 (116) 24.5 (132)
 16.5 (89) 20.7 (112) 50.0 (270)
) 15.7 (86) 6.0 (33) 9.7 (53)
all questions.
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specialist (6.4%, n = 37). The pharmacy and the cardiologist were
considered as more important by patients who use antithrombotic
medication compared to patients not using antithrombotic
medication (29.1% vs. 22.5%; p < 0.001 and 21.4% vs. 5.2%;
p < 0.001, respectively). In case of questions or problems with
medication, 63.8% (n = 369) of all patients reported that they
would contact the GP, followed by the pharmacist or pharmacy
assistant (16.6%, n = 96), cardiologist (7.4%, n = 43), GP nurse
practitioner (3.3%, n = 19) and specialist (3.6%, n = 21). Again, there
was a difference between patients using antithrombotic medica-
tion and patients not using antithrombotics: the pharmacy and
cardiologist were considered as more important by patients using
antithrombotics (20.9% vs. 14.4%; p < 0.001 and 14.8% vs. 3.7%;
p < 0.001, respectively. There were no signiﬁcant differences
between new users and chronic users of cardiovascular medication
for both the primary source of information and the health care
professional they would contact in case of questions or concerns
with their cardiovascular medication.
4. Discussion and conclusion
4.1. Discussion
This study showed that patients require more information on
their cardiovascular medication than they currently receive.
Patients were especially dissatisﬁed with the amount of informa-
tion received on the risks of side effects, what to do when
experiencing side effects, and how to judge the effectiveness of
medication.
Patients’ needs for and satisfaction with information is likely to
ﬂuctuate over time and with their experience of treatment [18,19].
In our study, new users of cardiovascular treatment indicated that
they were less satisﬁed with the information received than chronic
users. It could be that new users simply have had less opportunities
to receive the required information. In addition, the new users
have only recently been confronted with the fact that they are at
risk of developing cardiovascular disease and consequently may
have unanswered questions and concerns about the necessity of
medicine use and its side effects. Furthermore, patients using
antithrombotic medication were less satisﬁed with the informa-
tion received compared to those who did not use this medication.
Antithrombotic users have most likely experienced a cardiovascu-
lar event, which is likely to inﬂuence patients’ illness perceptions
thus inﬂuencing the amount of information they require. A
qualitative study in patients who had recently experienced a
myocardial infarction showed that patients’ information needs
change during their recovery process and thus require periodic
assessment and education updates [20].
Grouping patients based on medication beliefs could help to
identify those patients who will beneﬁt most from additional
information and counseling. This study showed that patients’
beliefs are important to consider when trying to understand
patients’ needs for information and counseling. Patients with an
ambivalent or skeptical attitude towards their cardiovascular
medication were unsatisﬁed with the information received more
often compared to patients with an accepting attitude. Other
studies also showed that patients who held stronger concerns
about treatment were less satisﬁed with the information they had
received [14,21], and would beneﬁt most from additional
counseling [8]. Furthermore, patients who receive speciﬁc
information on medication are more knowledgeable, have more
positive beliefs about medication and are more likely to adhere to
treatment [22,23]. Although there appears to be a relationship
between patients’ beliefs and their satisfaction with information,
we cannot infer causality. It is unclear whether patients’ beliefs andattitude towards medication determine their information needs or
vice versa. Patients who have a more skeptical attitude towards
medication may have greater information needs, but on the other
hand patients who feel that they lack information may also
develop a more skeptical attitude towards treatment. Yet, this does
not undermine our recommendation to elicit the patient’s views on
medication and address any questions, misconceptions or con-
cerns that the patient may have.
More than two-thirds of patients indicated that they have never
experienced ﬁve out of eight speciﬁc counseling activities at the
pharmacy. Two-thirds of the patients considered the prescribing
physician to be the primary provider of information and the ﬁrst to
contact if they had questions or problems with their cardiovascular
medication. Only one in four patients indicated the pharmacist to
be the primary source of information and for one in six patients the
pharmacist was the ﬁrst to contact in case of problems.
Although pharmacists in The Netherlands currently adopt a
crucial role in the management of chronic illness by educating and
counseling, apparently most patients still seem to be unfamiliar
with this role. Similar to our study, other studies have shown that
patients are generally unfamiliar with the pharmacist’s task as
information provider and caregiver [24–26]. A review of counsel-
ing practices of Puspitasari et al. showed that the rates of
counseling provided in pharmacies reported by consumers ranged
from 8% to 56% [27]. Counseling mostly focused on providing
information on medicine administration, while information on the
safety aspects, such as side effects, interactions and contra-
indications, was less likely to be given [27,28]. This is unfortunate
as counseling on these aspects may enable pharmacists to detect
and address the problems that patients experience with their
medication. Pharmacists are equiped to educate and counsel
patients on the importance of medication adherence and potential
adverse effects. Interventions delivered by pharmacists have
shown to improve cardiovascular outcomes, like the control of
blood pressure, heart failure and glycated haemoglobin [29–31].
Furthermore, pharmacists have been shown to uncover problems
with medication, that for various reasons remained undetected by
the GP [32]. Clifford et al. showed beneﬁts from pharmacists
meeting patients’ needs for information and advice soon after
starting chronic treatment: patients reported fewer medicine-
related problems, had more positive beliefs about their medication
and were more adherent than patients who had not received
additional information and advice from the pharmacist at that time
[23].
4.1.1. Limitations and strengths
Although a response rate of over 40% could be considered
reasonable, it may have introduced some selection bias. Comparing
respondents and non-respondents, there were some differences:
non-respondents were younger and more frequently used
benzodiapines and antidepressants. Therefore, we cannot exclude
that non-respondents would have rated the amount of information
received and the frequency of counseling at the pharmacy
differently from the respondents. A possible second limitation is
that there could be a bias in the selection of pharmacies. The
pharmacies that were invited to participate are part of a large
research and education network, consisting of about 900
community pharmacies, which is half of all pharmacies in The
Netherlands. Therefore we do not expect the pharmacies in the
network to be different from other pharmacies with regard to their
level of counseling. A further limitation is that the questionnaire
asks patients to rate the information and counseling about
cardiovascular drugs as a whole, not speciﬁcally about the types
of medication, such as antihypertensives, statins or antithrombo-
tics. Asking patients about speciﬁc medicines might have enriched
the ﬁndings. However, whether patients would be able to separate
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ﬁnal limitation is the subjective nature of patients’ own views
about the medication information they have received. We did not
measure the absolute quantity or quality of the information given,
so a dissatisfaction does not necessarily imply that health care
professionals did not provide the information rated by the patient.
Indeed, previous studies showed that patients forget substantial
amounts of the provided information [33,34]. However, this does
not detract from our conclusion that patients are dissatisﬁed with
the information given, and that needs to be addressed.
The strength of our study is the linking of data directly obtained
from patients through questionnaires with the pharmacy dispens-
ing data. This enabled the selection of the two groups of patients,
i.e. new users and chronic users, and enriched the information we
had on the patients. Furthermore, due to the availability of the
pharmacy dispensing data, it was possible to compare some
demographic and medication characteristics of respondents and
non-respondents.
4.2. Conclusion
The ﬁndings point to a considerable degree of dissatisfaction
with the information received by patients taking cardiovascular
medications. Moreover, a majority of patients have only received a
limited scope of medication counseling in the pharmacy.
4.3. Practice implications
Information and counseling should be tailored to patients’
needs and concerns about cardiovascular medication and the
experience patients already have with the treatment of cardiovas-
cular conditions.
Pharmacists could enhance their role in supporting patients
using cardiovascular medication.
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